Stifel Nicolaus Reiterates “Buy” Rating for Krystal Biotech (NASDAQ:KRYS)

Stifel Nicolaus restated their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a research report report published on Tuesday, Benzinga reports. Stifel Nicolaus currently has a $204.00 price target on the stock, up from their previous price target of $178.00.

A number of other research firms have also commented on KRYS. Guggenheim raised their price objective on Krystal Biotech from $130.00 to $175.00 and gave the stock a buy rating in a research note on Tuesday, February 27th. Citigroup raised their price objective on Krystal Biotech from $160.00 to $195.00 and gave the stock a buy rating in a research note on Tuesday, February 27th. Finally, William Blair restated an outperform rating on shares of Krystal Biotech in a research note on Tuesday, February 27th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of Buy and a consensus target price of $164.22.

Krystal Biotech Trading Down 3.3 %

Shares of NASDAQ KRYS opened at $158.53 on Tuesday. The firm has a market cap of $4.52 billion, a P/E ratio of 1,981.87 and a beta of 0.85. Krystal Biotech has a 1-year low of $82.09 and a 1-year high of $189.97. The business’s 50 day moving average is $159.74 and its 200-day moving average is $130.06.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, February 26th. The company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.82. The firm had revenue of $42.14 million for the quarter, compared to the consensus estimate of $27.43 million. During the same quarter last year, the business posted ($1.25) EPS. Analysts forecast that Krystal Biotech will post 1.89 EPS for the current year.

Insider Activity

In other news, CAO Kathryn Romano sold 2,500 shares of Krystal Biotech stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $130.00, for a total value of $325,000.00. Following the transaction, the chief accounting officer now owns 12,556 shares in the company, valued at approximately $1,632,280. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the sale, the insider now owns 1,550,882 shares of the company’s stock, valued at approximately $265,138,786.72. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Kathryn Romano sold 2,500 shares of the firm’s stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $130.00, for a total value of $325,000.00. Following the sale, the chief accounting officer now directly owns 12,556 shares in the company, valued at approximately $1,632,280. The disclosure for this sale can be found here. In the last quarter, insiders have sold 40,587 shares of company stock worth $6,535,591. Insiders own 14.10% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

Several hedge funds have recently modified their holdings of the company. Commonwealth Equity Services LLC lifted its holdings in Krystal Biotech by 2.5% during the 3rd quarter. Commonwealth Equity Services LLC now owns 4,426 shares of the company’s stock worth $513,000 after buying an additional 110 shares during the period. PNC Financial Services Group Inc. lifted its holdings in Krystal Biotech by 50.0% during the 2nd quarter. PNC Financial Services Group Inc. now owns 372 shares of the company’s stock worth $44,000 after buying an additional 124 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in Krystal Biotech by 1.8% during the 4th quarter. The Manufacturers Life Insurance Company now owns 8,485 shares of the company’s stock worth $672,000 after buying an additional 150 shares during the period. Legal & General Group Plc lifted its holdings in Krystal Biotech by 2.2% during the 4th quarter. Legal & General Group Plc now owns 7,120 shares of the company’s stock worth $564,000 after buying an additional 155 shares during the period. Finally, State of Wisconsin Investment Board lifted its holdings in Krystal Biotech by 0.9% during the 2nd quarter. State of Wisconsin Investment Board now owns 16,727 shares of the company’s stock worth $1,964,000 after buying an additional 156 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).